RT Journal Article
SR Electronic
T1 Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor from the FDA Adverse Event Reporting System (FAERS)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.16.23295574
DO 10.1101/2023.09.16.23295574
A1 Shi, Alan
A1 Nguyen, Harold
A1 Kuo, C. Benson
A1 Beringer, Paul M.
YR 2023
UL http://medrxiv.org/content/early/2023/09/17/2023.09.16.23295574.abstract
AB Introduction The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been established in prospective clinical trials. Liver function test elevations were observed in a greater proportion of patients receiving ETI compared with placebo; however, the relatively small number of patients and short duration of study preclude detection of rare but clinically significant associations with drug-induced liver injury (DILI). To address this gap, we assessed the real-world risk of DILI associated with ETI through data mining of the FDA Adverse Event Reporting System (FAERS).Methods Disproportionality analyses were conducted on FAERS data from the fourth quarter of 2019 through the third quarter of 2022. Comparative patient demographics, onset time and outcomes for ETI-DILI were also obtained.Results 452 reports of DILI associated with ETI were found, representing 2.1% of all adverse event reports for ETI. All disproportionality measures were significant for ETI-DILI at p < 0.05; the reporting odds ratio (ROR) was comparable to that of drugs classified by FDA as “Most-DILI concern”. The most notable demographic finding was a male majority for ETI-DILI compared to a female majority for non ETI-DILI. Median ETI-DILI onset time was 50.5 days, and hospitalization was the second most common complication.Conclusion Using FAERS data, ETI was found to be disproportionality associated with DILI. Future research is needed to investigate the hepatotoxic mechanisms and assess potential mitigation strategies for ETI-induced hepatotoxicity.Article HighlightsUsing the FDA Adverse Event Reporting System database, ETI and DILI were found to be significantly associated (p < 0.05) for all disproportionality measures (PRR, ROR, IC, EGBM, Yates’ chi-squared).The ROR for ETI-DILI is greater than that of many “Most-DILI concern” drugs in the FDA DILIRank dataset but is not within the top 20 drugs associated with DILI.Patient reports for ETI-DILI were predominately male, in contrast to patient reports for other drugs and DILI.“Hospitalization” was the second most common patient outcome for ETI-DILI after “other serious outcomes”.Most patients had onset times within 3 months of initiation, several patients had an onset time greater than 1 year.Onset times indicate that liver function test monitoring should be initiated earlier than 3 months and potentially extend beyond 1 year in some patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Anton Yelchin Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.